OmniAb Financial Ratios
NASDAQ: OABIHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
4.79+0.13 (+2.79%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
OmniAb ratio analysis
OmniAb earned a net margin of -347.0% in FY 2025, down from -235.1% a year earlier. Return on equity reached -24.3%, meaning OmniAb generated -0.24 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
OmniAb financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Price / sales | 11.45 | 14.27 | 18.00 | 5.20 | 23.77 |
| Price / book | 0.80 | 1.31 | 1.96 | 0.90 | 3.53 |
| Operating margin | -369.5% | -282.3% | -203.2% | -45.1% | -102.5% |
| Net margin | -347.0% | -235.1% | -148.2% | -37.8% | -77.8% |
| Free cash flow margin | -198.3% | -157.4% | 2.1% | -35.1% | -28.0% |
| Return on equity (ROE) | -24.3% | -21.6% | -16.1% | -6.5% | -11.5% |
| Return on assets (ROA) | -21.5% | -19.1% | -13.5% | -5.3% | -8.9% |
| Current ratio | 4.02 | 4.52 | 4.11 | 4.80 | 1.10 |
| Revenue growth | -29.3% | -22.8% | -42.2% | 70.0% | — |